Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
20% autologous serum eye drops + artificial tears
- Development stage
- Unknown
- Lead developer
- Université de Sherbrooke
- Administration
- Ophthalmic
01
Overview
20% autologous serum eye drops + artificial tears is a combination therapy being investigated by the Université de Sherbrooke for the treatment of corneal epitheliopathy, specifically in patients with glaucoma using preserved antihypertensive drops. Autologous serum eye drops (ASED) are produced from the patient's own peripheral blood and contain a variety of epitheliotrophic factors, including epidermal growth factor (EGF), transforming growth factor-beta (TGF-β), fibroblast growth factor (FGF), vitamin A, and fibronectin. These components mimic the biochemical properties of natural tears and promote corneal epithelial cell proliferation, migration, and differentiation. The addition of standard artificial tears (such as Refresh Plus) provides further lubrication and volume to the ocular surface, addressing the dry eye symptoms and epithelial damage caused by chronic exposure to preservatives like benzalkonium chloride.
- Other names
- 20% ASED + ATAutologous serum eye drops + artificial tearsASED + AT
02
Targets
EGFR (Epidermal growth factor receptor)FGFR (FGFR family)IGF-1R (Insulin-like growth factor 1 receptor)TGFBR (TGF-beta receptor)
Beyond the preview
Go deeper on 20% autologous serum eye drops + artificial tears.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 20% autologous serum eye drops + artificial tears.